Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

3articles mentioning drugs

5drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: PD-1 inhibitor ×

PD-1 inhibitor

This drug is selected. Its supporting articles are shown below.

PD-1 inhibitor3

Articles mentioning PD-1 inhibitor

3 articles · page 1 of 1

617 A real-world study on effectiveness and safety of first-line bevacizumab/PD-1 inhibitor plus chemotherapy in advanced non-squamous non-small-cell lung cancer with drive gene-negative

jitc · abstract · 2025-11-04 · 3 matching annotations

84.1%

bevacizumab PD-1 inhibitor Lung cancer advanced driver gene-negative nsNSCLC chemotherapy

…hemotherapy demonstrated significantly improved PFS compared to bevacizumab plus chemotherapy in the primary analysis. While OS favored the…

583 Intrathecal PD-1 inhibitor combined with pemetrexed for leptomeningeal metastases from solid tumors: preliminary results from a phase I/II study (NCT 06462222)

jitc · abstract · 2025-11-04 · 1 matching annotations

78.7%

pemetrexed Intrathecal PD-1 inhibitor PD-1 inhibitor non-small cell lung cancer solid tumors small cell lung cancer Guangzhou Medical University breast cancer Affiliated Huizhou Hospital involved-field radiotherapy+1 more

… OS was not reached.Conclusions Intrathecal PD-1 inhibitor plus pemetrexed showed feasibility for LM from solid tumors with potential acti…

817 Intratumoral CCR8+CD4+FoxP3+ regulatory T cell infiltration predicts inferior clinical outcomes but superior immunotherapeutic responsiveness in the patients with gastric cancer

jitc · abstract · 2025-11-04 · 1 matching annotations

89.5%

pembrolizumab pembrolizumab-based PD-1 inhibitor CCR8 antagonist Gastric cancer Fudan University GC Zhongshan Hospital

…nical outcomes but superior immunotherapeutic responsiveness to pembrolizumab in GC. Transcriptomic and phenotypic analyses revealed that tum…